NEW YORK (360Dx) – Theradiag today announced a deal to provide its Lisa Tracker kits for monitoring Biogen's Flixabi (infliximab) biosimilar.

Biogen will now be able to supply Lisa Tracker monitoring kits in the competitive tenders in which it participates in France, where the therapeutic firm has marketed two biosimilar drugs, including Flixabi, an autoimmune disease treatment. Today's deal also allows Biogen to offer Lisa Tracker in other European countries.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.